Voloshin, Tali <br/><br/>
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jul 2020 
 - 1191-1204 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-020-02534-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents, Immunological--pharmacology<br/>Apoptosis<br/>Carcinoma, Hepatocellular--immunology<br/>Carcinoma, Lewis Lung--immunology<br/>Cell Proliferation<br/>Combined Modality Therapy<br/>Electric Stimulation Therapy--methods<br/>Female<br/>Humans<br/>Immunogenic Cell Death<br/>Liver Neoplasms--immunology<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays